NEO 财务： Neogenomics Inc AI 分析

Q: Neogenomics Inc 的关键财务报表是什么？

根据最新的财务报表（Form-10K），Neogenomics Inc 的总资产为 $1,638，净损失为 $-78

Q: NEO 的关键财务比率是什么？

Neogenomics Inc 的流动比率是 2.22，净利 margin 为 -11.81，每股销售为 $5.21。

Q: Neogenomics Inc 的收入按细分市场或地理位置如何划分？

Neogenomics Inc 最大收入来源是 Client Direct Billing，在最近的收益报告中收入为 475,444,000。就地区而言， United States 是 Neogenomics Inc 的主要市场，收入为 660,566,000。

Q: Neogenomics Inc 是否盈利？

不，根据最新的财务报表，Neogenomics Inc 的净损失为 $-78

Q: Neogenomics Inc 有负债吗？

是的，Neogenomics Inc 的负债为 735

Q: Neogenomics Inc 的流通股有多少？

Neogenomics Inc 的总流通股为 128.14

主页

股票

NEO

NEO 财务

Neogenomics Inc

$12.79

-0.31%

$-0.04

收盘价：Jan 16, 16:00:00 GMT-5

$12.48

-2.36%

$-0.3

盘后：Jan 16, 20:00:00 GMT-5

概述预测收益股息财务数据

关键数据

前收盘价

$12.83

开盘价

$12.83

当日区间

$12.48 - $13

52周范围

$4.72 - $15.32

交易量

3.7M

平均成交量

2.4M

每股收益（TTM）

-0.89

股息收益率

市值

$1.6B

什么是 NEO？

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,200 full-time employees. The company went IPO on 2012-12-10. The firm offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. The company operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.

功能特性

交易策略

资源

市场

收入

资产负债表

现金流量

年度

季度性

NEO 收入

以百万美元为单位的财务数据。财年为2月至次年1月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
营收	709	660	591	509	484	444
营收同比增长 (YoY)	10%	12%	16%	5%	9%	9%
营收成本	400	370	347	321	297	258
毛利润	308	290	244	187	187	185
销售、一般及管理费用	351	310	279	277	229	169
研发	35	29	25	28	21	8
营业费用	400	375	341	341	290	197
其他非经营性收入 (费用)	0	0	0	0	0	11
税前利润	-113	-80	-97	-159	-15	-14
所得税费用	0	-1	-9	-15	-6	-18
净利润	-113	-78	-87	-144	-8	4
净利润增长	47%	-10%	-40%	1,700%	-300%	-50%
稀释后流通股数	128.41	126.65	125.5	124.2	120	111.8
股份同比变动 (YoY)	1%	1%	1%	4%	7%	8%
每股收益 (摊薄)	-0.88	-0.62	-0.7	-1.16	-0.07	0.04
每股收益增长率	44%	-11%	-40%	1,557%	-275%	-50%
自由现金流	-17	-34	-30	-96	-90	-27
每股自由现金流	--	--	--	--	--	--
毛利率	43.44%	43.93%	41.28%	36.73%	38.63%	41.66%
营业利润率	-12.97%	-12.87%	-16.24%	-30.05%	-21.28%	-2.47%
净利率	-15.93%	-11.81%	-14.72%	-28.29%	-1.65%	0.9%
自由现金流利润率	-2.39%	-5.15%	-5.07%	-18.86%	-18.59%	-6.08%
EBITDA	-23	-13	-24	-84	-50	24
EBITDA 利润率	-3.24%	-1.96%	-4.06%	-16.5%	-10.33%	5.4%
EBITDA 中的折旧与摊销	69	72	72	69	53	35
EBIT	-92	-85	-96	-153	-103	-11
EBIT 利润率	-12.97%	-12.87%	-16.24%	-30.05%	-21.28%	-2.47%
有效税率	0%	1.25%	9.27%	9.43%	40%	128.57%

Follow-Up Questions

Neogenomics Inc 的关键财务报表是什么？



NEO 的关键财务比率是什么？



Neogenomics Inc 的收入按细分市场或地理位置如何划分？



Neogenomics Inc 是否盈利？



Neogenomics Inc 有负债吗？



Neogenomics Inc 的流通股有多少？



Neogenomics Inc（NEO）价格

NEO 股价走势图